Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was upgraded by research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Thursday. The brokerage currently has a $47.00 price objective on the stock, up from their prior price objective of $27.00. Leerink Swann’s price objective […]
